Abstract
This trial has evaluated a systematic prospective analysis of the efficacy and safety of BR in CLL patients in the routine clinical practice. It included 179 patients with verified CLL diagnosis and the presence of the indications for initiation of therapy according to the guidelines iwCLL who received BR regimen. The trial has shown that BR regime has high efficiency and relatively low toxicity in first line therapy of CLL and also is well tolerated in patients with comorbidity and impaired renal function. The efficiency of BR is lower in patients with IGHV-unmutated type of CLL. The achieving of the eradication of MRD in BM is the best predictor of PFS.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
